The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma

Summary Background SH2‐containing inositol‐5′‐phosphatase 1 (SHIP1) is an endogenous inhibitor of the phosphoinositide‐3‐kinase pathway that is involved in the activation and chemotaxis of inflammatory cells. AQX‐1125 is a first‐in‐class, oral SHIP1 activator with a novel anti‐inflammatory mode of a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical and experimental allergy 2014-09, Vol.44 (9), p.1146-1153
Hauptverfasser:	Leaker, B. R., Barnes, P. J., O'Connor, B. J., Ali, F. Y., Tam, P., Neville, J., Mackenzie, L. F., MacRury, T.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult airway hyperresponsiveness Allergens - administration & dosage Allergens - immunology Analysis of Variance Anti-Asthmatic Agents - pharmacology Anti-Asthmatic Agents - therapeutic use asthma Asthma - diagnosis Asthma - drug therapy Asthma - immunology Asthma - metabolism Bronchial Provocation Tests Cross-Over Studies Cyclohexanols - pharmacology Cyclohexanols - therapeutic use Exhalation Female Forced Expiratory Volume Humans Indans - pharmacology Indans - therapeutic use induced sputum inhaled allergen challenge Inositol Polyphosphate 5-Phosphatases Male Nitric Oxide - metabolism Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases Phosphatidylinositols - metabolism phosphoinositide-3-kinase Phosphoric Monoester Hydrolases - metabolism Risk Factors Severity of Illness Index SH2-containing inositol-5′-phosphatase 1 Signal Transduction Sputum Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!